News
We send the latest information from SMC Laboratories.
February 4th is World Cancer Day!
World Cancer Day was established on February 4th, 2000, at the World Summit Against Cancer for the New Millennium in Paris initiated by UICC (Union for International Cancer Control). It is a day where people all around the world come together and join in the fight against cancer by raising public awareness of the disease….
SMC announces Announcement of webinar 【High quality non-clinical study designs】
Today we are excited to invite you to join our Online Linkedin Webinar that will be taking place next week on January 19th (JST) from 10:30 AM. In this webinar series we have being looking at examples of both clinical NASH trials as well as non-clinical study designs. For the 3rd installment in this…
NASH, the fastest growing cause of liver cancer
We wish you a Happy and Prosperous New Year! If you are currently planning to begin a project this year, we would love to support you in any way we can, including conducting one of our high quality pharmacology studies. Today, we would like to share with you a little bit about the…
Fibrosis is involved in many diseases and disease-related deaths
Today's topic is Fibrosis. We would like to discuss with you the importance of therapeutic treatments that target fibrosis. Fibrosis is involved in many diseases, so even if fibrosis is not your direct target, please read on. Fibrosis can occur in many different organs. It is caused by a disruption in the wound healing…
Introduction of MAFLD criteria and the disease model
Today, we would like to introduce metabolic dysfunction-associated fatty liver disease (MAFLD), a new concept in the study of fatty liver disease. Non-alcoholic fatty liver disease (NAFLD) is defined as the presence of fatty liver disease in the absence of any known causes of steatosis. The number of NAFLD cases are growing worldwide due…
The effect of the gut-liver axis dysfunction in liver disease
Today, I would like to introduce the relationship between Nonalcoholic steatohepatitis (NASH) and the gut. Factors contributing to the progression of the NASH include oxidative stress, lipotoxicity, and mitochondrial dysfunction, and recently much attention has been focused on gut-liver axis dysfunction. The gut and the liver are connected by a blood vessel called…
Today, September 21th, is World Alzheimer’s Day!
We recently mentioned World Alzheimer's Month, including World Alzheimer's Day (Previous article), and today we would like to share SMC's thoughts on the development of a medicine for the treatment of Alzheimer's disease. There are currently five FDA-approved drugs for Alzheimer's disease (Donepezil, Rivastigmine, Galantamine, Memantine, and Aducanumab). These treatments can be divided into…
The importance of the NAFLD activity score and the STAM™ model’s clinical relevance
In this issue, we would like to introduce the NAFLD activity score (NAS), which is one of the main endpoints used in the development of drug candidates for NASH, and the role it plays in our proprietary STAM™ model. But, first, what is NAS and how does it relate to the study of NASH?…
September is World Alzheimer’s Month!
In recognition of September 21st being World Alzheimer’s Day, why don’t we deepen our understanding of Alzheimer's disease? In 1994, the “Alzheimer's Disease International” (ADI), in collaboration with the World Health Organization (WHO), established September 21st as “World Alzheimer's Day” to raise awareness for people who suffer from dementia. In addition to this, September…
July 28th is World Hepatitis Day!
In recognition of July 28th being World Hepatitis Day, we here at SMC thought it might be a good idea to help everyone around the globe have a deeper understanding of hepatitis, so please read on if you would like to learn more. In 2010, the World Health Organization (WHO) designated July 28th as…